- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
CDC Panel Backs RSV Shots for Seniors
An advisory panel of the U.S.Centers for Disease Control and Prevention voted on Wednesday to recommend the first RSV vaccines for seniors.
The U.S. Food and Drug Administration has already approved the vaccines, one made by GSK called Arexvy and a version from Pfizer Inc. called Abrysvo.
During the meeting, the panel called for “shared clinical decision-making” between doctors and patients to discuss benefits and risks, but stopped short of recommending that all seniors get the shots.
Younger seniors, those in their early 60s, will have fewer risks of severe disease from the virus, CBS News reported. The vaccine trials did have a small number of very rare, but severe, “inflammatory neurologic events.”
“Lives, hospitalizations, we could have a significant impact this year. So that’s why we wouldn’t want to delay further,” panel chair Dr. Camille Kotton said during the meeting, CBS News reported.
CDC officials plan to closely follow data from vaccine safety systems as seniors begin getting the RSV vaccines.
“I want to remind everyone that we have one of the best vaccine safety systems in the world. We have the ability to rapidly acquire information, rapidly assess it and act on it. We saw that during the COVID pandemic, that system is viable and is in place,” the CDC’s Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, told the panel, CBS News reported.
Prices have not been finalized, but GSK has said its vaccine could carry a price tag of $200 to $295 per dose. Pfizer has said its shot will be between $180 and $270, CBS News reported.
Infants may also soon have an RSV vaccine. The FDA is expected to consider those vaccines later this year.
“This field will undoubtedly change within the next five to 10 years. We’ll learn a lot more. So we’re trying to make a decision as best we can with the data we have now, at this time,” Kotton said.
More information
The U.S. Centers for Disease Control and Prevention has more on RSV.
SOURCE: CBS News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During MidlifeTUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
-
Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer ScreeningIn guidelines that may encourage more women to get...
- December 10, 2024
